Drug archive
Etretinate (Systemic)
Archived drug information. This USP DI monograph is kept for reference and dates from the mid-2000s. Doses, warnings, interactions and brand names may have changed, and some products are no longer sold. Always follow your prescriber, your pharmacist and the current label, for example on DailyMed.
Category
- Antipsoriatic, systemic
Description
Etretinate (e-TRET-i-nate) is used to treat severe psoriasis. It is usually used only after other medicines have been tried and have failed to help the psoriasis.
Etretinate must not be used to treat women who are able to bear children unless other forms of treatment have been tried first and have failed. Etretinate must not be taken during pregnancy, because it causes birth defects in humans. In addition, if you take etretinate, you must plan on never having children in the future. If you are able to bear children, it is very important that you read, understand, and follow the pregnancy warnings for etretinate .
It is also recommended that etretinate not be used to treat children unless all other forms of treatment have been tried first and have failed. Etretinate may interfere with bone growth. In addition, children may be more sensitive to the side effects of the medicine.
This medicine was withdrawn from the U.S. market in March 1998 and the Canadian market in January 1996.